Publications by authors named "Adam Cursley"
Article Synopsis
- The study analyzed raltegravir pharmacokinetics using data from the NEAT001/ARNS143 study involving 349 patients at weeks 4 and 24, utilizing a complex statistical modeling approach.
- It found that demographics and specific genetic variants (SNPs) did not significantly affect raltegravir pharmacokinetics or pharmacodynamics, indicating a lack of clear relationships between these factors.
- However, a genetic variant (UGT1A1*28/*28) was linked to a reduced risk of virological failure at week 96, though this association was influenced by other baseline variables like HIV-1 viral load.
Idelalisib (IDL) is an oral first-in-class phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO-idel was a protocol-led, retrospective study of 110 patients [n = 27 front-line (1L)] who received IDL-R.
View Article and Find Full Text PDFPopulation pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
J Antimicrob Chemother
March 2020
Objectives: NEAT001/ANRS143 demonstrated non-inferiority of once-daily darunavir/ritonavir (800/100 mg) + twice-daily raltegravir (400 mg) versus darunavir/ritonavir + tenofovir disoproxil fumarate/emtricitabine (245/200 mg once daily) in treatment-naive patients. We investigated the population pharmacokinetics of darunavir, ritonavir, tenofovir and emtricitabine and relationships with demographics, genetic polymorphisms and virological failure.
Methods: Non-linear mixed-effects models (NONMEM v.